Tag: toll-like receptors
Addressing the Challenges of Bioconjugate Medicines
Abstract
The continuing advancements in bioconjugate medicines from delivery of potent cytotoxins to vaccine-, oligonucleotide-, radionuclide-, immunomodulator- and check-point inhibitor-conjugates, can start to address the...
How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads...
Antibody-drug Conjugates or ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise, targeted, therapeutic applications.
Combining the...
